<?xml version="1.0" encoding="UTF-8"?>
<p id="Par44">We included seven observational studies (six cohort studies and one case control study) in the meta-analysis (Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>). A case control and four cohort studies were conducted in China [
 <xref ref-type="bibr" rid="CR38">38</xref>, 
 <xref ref-type="bibr" rid="CR41">41</xref>, 
 <xref ref-type="bibr" rid="CR44">44</xref>, 
 <xref ref-type="bibr" rid="CR45">45</xref>, 
 <xref ref-type="bibr" rid="CR48">48</xref>] and two other cohort studies were undertaken in South Africa [
 <xref ref-type="bibr" rid="CR42">42</xref>] and the Philippines [
 <xref ref-type="bibr" rid="CR43">43</xref>] (see Table 
 <xref rid="Tab2" ref-type="table">2</xref>). One cohort included COVID-19/HIV/TB and COVID-19/TB co-infected groups were included in the TB occurrence outcome, with a total sample of 2015 participants. COVID-19 severity included three cohort studies and one case control for which the total sample size was 2074 participants. A total of 22,838 and 23,017 participants were included in recovery and mortality rates respectively. Each of them included two and three cohort studies respectively. The results of the meta-analysis based on seven observational studies including HIV/TB or TB as exposures that may impact on COVID-19 outcomes were described as follows:
</p>
